pPACKH1 HIV Lentivector Packaging Kit

Generate high titers of transduction-ready pseudoviral particles with this HIV-based Lentivector Packaging Kit
  • Effectively leverage the powerful lentiviral transduction platform with SBI’s optimized HIV-based and FIV-based packaging systems
  • Easily generate high-titer lentiviral preparations
  • Efficiently deliver most third-generation lentivector expression constructs
  • Successfully reach:
    • A wide variety of mammalian cells with VSV-G pseudotyped lentiviral particles
    • A broad range of cell types including dividing and quiescent cells, primary cells, stem cells, neuronal cells, endothelial cells, and more

Products

Catalog Number Description Size Price Quantity Add to Cart
LV500A-1 pPACKH1 HIV Lentivector Packaging Kit 10 Transfections $549
- +
LV510A-1 pPACKH1-XL HIV Lentivector Packaging Kit 25 Transfections $1210
- +

Overview

Overview

Produce high-titer lentivirus with this HIV-based Lentivector Packaging Kit

Designed to efficiently package most third-generation lentivectors, the pPACKH1 HIV Lentivector Packaging Kit makes it easy to deliver and express lentiviral constructs in a wide-range of mammalian cells.

  • Effectively leverage the powerful lentiviral transduction platform with SBI’s optimized HIV-based and FIV-based packaging systems
  • Easily generate high-titer lentiviral preparations
  • Efficiently deliver most third-generation lentivector expression constructs
  • Successfully reach:
    • A wide variety of mammalian cells with VSV-G pseudotyped lentiviral particles
    • A broad range of cell types including dividing and quiescent cells, primary cells, stem cells, neuronal cells, endothelial cells, and more

The pPACKH1 Packaging Plasmid Mix consists of three plasmids that produce all the structural and replication proteins needed to transcribe and package an RNA copy of the expression lentivector into recombinant, VSV-G-pseudotyped lentiviral particles. Just co-transfect the pPACKH1 Plasmids and your lentivector construct into 293TN cells or other lentiviral production cells, isolate virus particles, and transduce into target cells. Upon transduction, the lentivector construct becomes stably integrated into the genome of the target cells for long-term expression of genes, miRNAs, shRNAs, etc.

References

How It Works

How It Works

The lentivirus packaging, production, and transduction workflow

Use the pPACKH1 HIV Lentivector Packaging Kit to package your lentivector expression construct into high-titer lentivirus particle preparations

Supporting Data

Supporting Data

SBI’s pPACKH1 and pPACKF1 Lentivector Packaging Systems possess broad cellular tropism

SBI’s pPACKH1 and pPACKF1 Lentivector Packaging Systems possess broad cellular tropism

FAQs

The pPACKH1 HIV Lentivector Packaging Kit is designed to efficiently package most third-generation lentivectors, allowing for the delivery and expression of lentiviral constructs in a wide range of mammalian cells.
The pPACKH1 HIV Lentivector Packaging Kit can transduce a broad range of cell types, including dividing and quiescent cells, primary cells, stem cells, neuronal cells, endothelial cells, and more.
The pPACKH1 Packaging Plasmid Mix contains three plasmids that produce all the structural and replication proteins needed to transcribe and package an RNA copy of the expression lentivector into recombinant, VSV-G-pseudo typed lentiviral particles. Co-transfect the pPACKH1 Plasmids and your lentivector construct into 293TN cells or other lentiviral production cells, isolate virus particles, and transduce into target cells. Upon transduction, the lentivector construct becomes stably integrated into the genome of the target cells for long-term expression of genes, miRNAs, shRNAs, etc.
The pPACKH1 HIV Lentivector Packaging Kit enables you to easily generate high-titer lentiviral preparations by co-transfecting the pPACKH1 Plasmids and your lentivector construct into 293TN cells or other lentiviral production cells.
The pPACKH1 HIV Lentivector Packaging Kit is based on an HIV-derived system, while the pPACKF1 FIV (Cat. # LV100A-1 and LV100A-5) Lentivector Packaging Kit uses an FIV-derived system. Both systems are designed to effectively leverage the powerful lentiviral transduction platform for gene delivery and expression in a wide range of mammalian cells.
To speak to a specialist, you can either contact System Biosciences via our website, e-mail us at info@systembio.com, or call our toll-free number at 1-888-266-5066.
Yes, the pPACKH1 HIV Lentivector Packaging Kit is available in two sizes: LV500A-1 with 10 transfections and LV510A-1 with 25 transfections. Price is subject to change from year to year.

Resources

Citations

  • Miyakawa, Y, et al. (2024) Gut bacteria-derived membrane vesicles induce colonic dysplasia by inducing DNA damage in colon epithelial cells. Cellular and Molecular Gastroenterology and Hepatology. 2024;. Link: Cellular and Molecular Gastroenterology and Hepatology
  • Jancewicz, I, et al. (2024) New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII. 2024; 73(2):30. PM ID: 38279989
  • Chai, Y, et al. (2024) Study on the Role and Mechanism of Exosomes Derived from Dental Pulp Stem Cells in Promoting Regeneration of Myelin Sheath in Rats with Sciatic Nerve Injury. Molecular neurobiology. 2024;. PM ID: 38285287
  • Ramadan, F, et al. (2024) Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma. Cancers. 2024; 16(9):1652. Link: Cancers
  • Lee, PWT, et al. (2024) Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner. British journal of cancer. 2024;. PM ID: 38740970
  • Dimberg, L, et al. (2024) Data from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. American Association for Cancer Research. 2024;. Link: American Association for Cancer Research
  • Tam, K, et al. (2024) Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in post-transplant lymphoproliferative disorder. bioRxiv. 2024;. Link: bioRxiv
  • Liao, YN, et al. (2024) Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2024; 38(10):e23705. PM ID: 38805171
  • Wang, X, et al. (2024) The role and mechanism of IFITM1 in developing acquired cisplatin resistance in small cell lung cancer. Heliyon. 2024; 10(10):e30806. PM ID: 38803858
  • Hsiao, M, et al. (2024) Molecular Display of the Animal Meta-Venome for Discovery of Novel Therapeutic Peptides. bioRxiv. 2024;. Link: bioRxiv
  • Mo, Y, et al. (2023) Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Molecular cancer. 2023; 22(1):4. PM ID: 36624516
  • Zhou, Q, et al. (2023) Catechol-O-Methyltransferase Loss Drives Cell-Specific Nociceptive Signaling via the Enteric COMT/miR-155/TNF-α Axis. Gastroenterology. 2023;. PM ID: 36623778
  • Ko, JY, et al. (2023) Micro Ribonucleic Acid-29a (miR-29a) Antagonist Normalizes Bone Metabolism in Osteogenesis Imperfecta (OI) Mice Model. Biomedicines. 2023; 11(2). PM ID: 36831000
  • Li, J, et al. (2023) Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma. BMC cancer. 2023; 23(1):110. PM ID: 36721112
  • Guan, Y, et al. (2023) Ginsenoside Rg1 attenuates cerebral ischemia-reperfusion injury through inhibiting the inflammatory activation of microglia. Experimental cell research. 2023; 426(1):113552. PM ID: 36914061
  • Cui, H, et al. (2023) Effect and Mechanism of lncRNA-PCMF1/hsa-miR-137/Twist1 Axis Involved in the EMT Regulation of Prostate Cancer Cells. Molecular biotechnology. 2023;. PM ID: 36906874
  • Krohl, P, et al. (2023) Discovery of antibodies targeting multipass transmembrane proteins using a suspension cell-based evolutionary approach. Cell Reports Methods. 2023; 3(3):100429. Link: Cell Reports Methods
  • Hong, J, et al. (2023) MiR-3180 inhibits hepatocellular carcinoma growth and metastasis by targeting lipid synthesis and uptake. Cancer cell international. 2023; 23(1):66. PM ID: 37041584
  • Gao, S, et al. (2023) MicroRNA-322 inhibition of calcification of arterial smooth muscle cells by regulation of galactosyltransferase 1-associating protein UBE2Q1 and Runx2. Cardiology Plus. 2023; Publish Ahead of Print. Link: Cardiology Plus
  • Ichinohe, N, et al. (2023) CINC-2 and miR-199a-5p in EVs secreted by transplanted Thy1+ cells activate hepatocytic progenitor cell growth in rat liver regeneration. Stem cell research & therapy. 2023; 14(1):134. PM ID: 37194082

Products

Catalog Number Description Size Price Quantity Add to Cart
LV500A-1 pPACKH1 HIV Lentivector Packaging Kit 10 Transfections $549
- +
LV510A-1 pPACKH1-XL HIV Lentivector Packaging Kit 25 Transfections $1210
- +

Overview

Overview

Produce high-titer lentivirus with this HIV-based Lentivector Packaging Kit

Designed to efficiently package most third-generation lentivectors, the pPACKH1 HIV Lentivector Packaging Kit makes it easy to deliver and express lentiviral constructs in a wide-range of mammalian cells.

  • Effectively leverage the powerful lentiviral transduction platform with SBI’s optimized HIV-based and FIV-based packaging systems
  • Easily generate high-titer lentiviral preparations
  • Efficiently deliver most third-generation lentivector expression constructs
  • Successfully reach:
    • A wide variety of mammalian cells with VSV-G pseudotyped lentiviral particles
    • A broad range of cell types including dividing and quiescent cells, primary cells, stem cells, neuronal cells, endothelial cells, and more

The pPACKH1 Packaging Plasmid Mix consists of three plasmids that produce all the structural and replication proteins needed to transcribe and package an RNA copy of the expression lentivector into recombinant, VSV-G-pseudotyped lentiviral particles. Just co-transfect the pPACKH1 Plasmids and your lentivector construct into 293TN cells or other lentiviral production cells, isolate virus particles, and transduce into target cells. Upon transduction, the lentivector construct becomes stably integrated into the genome of the target cells for long-term expression of genes, miRNAs, shRNAs, etc.

References

How It Works

How It Works

The lentivirus packaging, production, and transduction workflow

Use the pPACKH1 HIV Lentivector Packaging Kit to package your lentivector expression construct into high-titer lentivirus particle preparations

Supporting Data

Supporting Data

SBI’s pPACKH1 and pPACKF1 Lentivector Packaging Systems possess broad cellular tropism

SBI’s pPACKH1 and pPACKF1 Lentivector Packaging Systems possess broad cellular tropism

FAQs

The pPACKH1 HIV Lentivector Packaging Kit is designed to efficiently package most third-generation lentivectors, allowing for the delivery and expression of lentiviral constructs in a wide range of mammalian cells.
The pPACKH1 HIV Lentivector Packaging Kit can transduce a broad range of cell types, including dividing and quiescent cells, primary cells, stem cells, neuronal cells, endothelial cells, and more.
The pPACKH1 Packaging Plasmid Mix contains three plasmids that produce all the structural and replication proteins needed to transcribe and package an RNA copy of the expression lentivector into recombinant, VSV-G-pseudo typed lentiviral particles. Co-transfect the pPACKH1 Plasmids and your lentivector construct into 293TN cells or other lentiviral production cells, isolate virus particles, and transduce into target cells. Upon transduction, the lentivector construct becomes stably integrated into the genome of the target cells for long-term expression of genes, miRNAs, shRNAs, etc.
The pPACKH1 HIV Lentivector Packaging Kit enables you to easily generate high-titer lentiviral preparations by co-transfecting the pPACKH1 Plasmids and your lentivector construct into 293TN cells or other lentiviral production cells.
The pPACKH1 HIV Lentivector Packaging Kit is based on an HIV-derived system, while the pPACKF1 FIV (Cat. # LV100A-1 and LV100A-5) Lentivector Packaging Kit uses an FIV-derived system. Both systems are designed to effectively leverage the powerful lentiviral transduction platform for gene delivery and expression in a wide range of mammalian cells.
To speak to a specialist, you can either contact System Biosciences via our website, e-mail us at info@systembio.com, or call our toll-free number at 1-888-266-5066.
Yes, the pPACKH1 HIV Lentivector Packaging Kit is available in two sizes: LV500A-1 with 10 transfections and LV510A-1 with 25 transfections. Price is subject to change from year to year.

Citations

  • Miyakawa, Y, et al. (2024) Gut bacteria-derived membrane vesicles induce colonic dysplasia by inducing DNA damage in colon epithelial cells. Cellular and Molecular Gastroenterology and Hepatology. 2024;. Link: Cellular and Molecular Gastroenterology and Hepatology
  • Jancewicz, I, et al. (2024) New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII. 2024; 73(2):30. PM ID: 38279989
  • Chai, Y, et al. (2024) Study on the Role and Mechanism of Exosomes Derived from Dental Pulp Stem Cells in Promoting Regeneration of Myelin Sheath in Rats with Sciatic Nerve Injury. Molecular neurobiology. 2024;. PM ID: 38285287
  • Ramadan, F, et al. (2024) Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma. Cancers. 2024; 16(9):1652. Link: Cancers
  • Lee, PWT, et al. (2024) Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner. British journal of cancer. 2024;. PM ID: 38740970
  • Dimberg, L, et al. (2024) Data from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. American Association for Cancer Research. 2024;. Link: American Association for Cancer Research
  • Tam, K, et al. (2024) Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in post-transplant lymphoproliferative disorder. bioRxiv. 2024;. Link: bioRxiv
  • Liao, YN, et al. (2024) Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2024; 38(10):e23705. PM ID: 38805171
  • Wang, X, et al. (2024) The role and mechanism of IFITM1 in developing acquired cisplatin resistance in small cell lung cancer. Heliyon. 2024; 10(10):e30806. PM ID: 38803858
  • Hsiao, M, et al. (2024) Molecular Display of the Animal Meta-Venome for Discovery of Novel Therapeutic Peptides. bioRxiv. 2024;. Link: bioRxiv
  • Mo, Y, et al. (2023) Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Molecular cancer. 2023; 22(1):4. PM ID: 36624516
  • Zhou, Q, et al. (2023) Catechol-O-Methyltransferase Loss Drives Cell-Specific Nociceptive Signaling via the Enteric COMT/miR-155/TNF-α Axis. Gastroenterology. 2023;. PM ID: 36623778
  • Ko, JY, et al. (2023) Micro Ribonucleic Acid-29a (miR-29a) Antagonist Normalizes Bone Metabolism in Osteogenesis Imperfecta (OI) Mice Model. Biomedicines. 2023; 11(2). PM ID: 36831000
  • Li, J, et al. (2023) Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma. BMC cancer. 2023; 23(1):110. PM ID: 36721112
  • Guan, Y, et al. (2023) Ginsenoside Rg1 attenuates cerebral ischemia-reperfusion injury through inhibiting the inflammatory activation of microglia. Experimental cell research. 2023; 426(1):113552. PM ID: 36914061
  • Cui, H, et al. (2023) Effect and Mechanism of lncRNA-PCMF1/hsa-miR-137/Twist1 Axis Involved in the EMT Regulation of Prostate Cancer Cells. Molecular biotechnology. 2023;. PM ID: 36906874
  • Krohl, P, et al. (2023) Discovery of antibodies targeting multipass transmembrane proteins using a suspension cell-based evolutionary approach. Cell Reports Methods. 2023; 3(3):100429. Link: Cell Reports Methods
  • Hong, J, et al. (2023) MiR-3180 inhibits hepatocellular carcinoma growth and metastasis by targeting lipid synthesis and uptake. Cancer cell international. 2023; 23(1):66. PM ID: 37041584
  • Gao, S, et al. (2023) MicroRNA-322 inhibition of calcification of arterial smooth muscle cells by regulation of galactosyltransferase 1-associating protein UBE2Q1 and Runx2. Cardiology Plus. 2023; Publish Ahead of Print. Link: Cardiology Plus
  • Ichinohe, N, et al. (2023) CINC-2 and miR-199a-5p in EVs secreted by transplanted Thy1+ cells activate hepatocytic progenitor cell growth in rat liver regeneration. Stem cell research & therapy. 2023; 14(1):134. PM ID: 37194082